These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24930471)

  • 1. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.
    Nutman A; Glick R; Temkin E; Hoshen M; Edgar R; Braun T; Carmeli Y
    Clin Microbiol Infect; 2014 Dec; 20(12):O1028-34. PubMed ID: 24930471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
    Russo A; Gullì SP; D'Avino A; Borrazzo C; Carannante N; Dezza FC; Covino S; Polistina G; Fiorentino G; Trecarichi EM; Mastroianni CM; Torti C; Oliva A
    Int J Antimicrob Agents; 2024 Jul; 64(1):107190. PubMed ID: 38697579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact and risk factors for developing pneumogenic bacteremia in carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in the intensive care unit: A multicenter retrospective study.
    Wang SH; Teng CK; Chan MC; Yang KY; Sheu CC; Liang SJ; Huang WH; Feng JY; Chen CM; Weng ZX; Peng CK;
    Int J Infect Dis; 2024 Sep; 146():107128. PubMed ID: 38852767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with Acinetobacter baumannii bacteremia.
    Lan M; Dongmei K; Guodong S; Haifeng Y; Guofeng C; Mengting C; Xiaoyun F
    BMC Infect Dis; 2024 Apr; 24(1):448. PubMed ID: 38671347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
    Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
    Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and molecular predictors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: A retrospective cohort study.
    Suh JW; Park SM; Ju YK; Yang KS; Kim JY; Kim SB; Sohn JW; Yoon YK
    J Microbiol Immunol Infect; 2024 Feb; 57(1):148-155. PubMed ID: 38057202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.
    Wang M; Ge L; Chen L; Komarow L; Hanson B; Reyes J; Cober E; Alenazi T; Zong Z; Xie Q; Liu Z; Li L; Yu Y; Gao H; Kanj SS; Figueroa J; Herc E; Cordova E; Weston G; Ananth Tambyah P; Garcia-Diaz J; Kaye KS; Dhar S; Munita JM; Salata RA; Vilchez S; Stryjewski ME; Villegas Botero MV; Iovleva A; Evans SR; Baum K; Hill C; Kreiswirth BN; Patel R; Paterson DL; Arias CA; Bonomo RA; Chambers HF; Fowler VG; Satlin MJ; van Duin D; Doi Y;
    Clin Infect Dis; 2024 Feb; 78(2):248-258. PubMed ID: 37738153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: A multicentre retrospective propensity score-matched study.
    Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK;
    Int J Antimicrob Agents; 2024 Jan; 63(1):107044. PubMed ID: 38040319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital outbreak of Carbapenem-resistant acinetobacter baumannii in the context of local facility transmission.
    Darwish MM; Catalan MI; Wilson T; McGlynn CC; Suhd-Brondstatter J; Dow AL; Kingsley A; Reilly ME; Cohen SH; Desai AN
    Am J Infect Control; 2024 Jun; 52(6):739-741. PubMed ID: 38246493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.
    Lee YT; Chiang MC; Kuo SC; Wang YC; Lee IH; Chen TL; Yang YS
    PLoS One; 2016; 11(9):e0163271. PubMed ID: 27644087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory microbiome and clinical course of carbapenem-resistant Acinetobacter baumannii pneumonia in critically Ill patients.
    Yoon JG; Lim S; Hyun HJ; Seong H; Noh JY; Song JY; Kim WJ; Cheong HJ
    Medicine (Baltimore); 2024 Aug; 103(31):e38988. PubMed ID: 39093794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the virulence and genetic differences of carbapenem-resistant
    Huang XL; Ning NZ; Li BA; Wang H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 May; 58(5):649-655. PubMed ID: 38715505
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors for transmission of carbapenem-resistant Acinetobacter baumannii in outbreak situations: results of a case-control study.
    Schlosser B; Weikert B; Fucini GB; Kohlmorgen B; Kola A; Weber A; Thoma N; Behnke M; Schwab F; Gastmeier P; Geffers C; Aghdassi SJS
    BMC Infect Dis; 2024 Jan; 24(1):120. PubMed ID: 38263063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and application of a risk nomogram for the prediction of risk of carbapenem-resistant Acinetobacter baumannii infections in neuro-intensive care unit: a mixed method study.
    Li Y; Gao X; Diao H; Shi T; Zhang J; Liu Y; Zeng Q; Ding J; Chen J; Yang K; Ma Q; Liu X; Yu H; Lu G
    Antimicrob Resist Infect Control; 2024 Jun; 13(1):62. PubMed ID: 38867312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis.
    Onorato L; de Luca I; Monari C; Coppola N
    J Infect; 2024 Mar; 88(3):106113. PubMed ID: 38331328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited impact of bacterial virulence on early mortality risk factors in Acinetobacter baumannii bacteremia observed in a Galleria mellonella model.
    Ham SY; Chun JY; Song KH; Kang CK; Park JS; Jo HB; Ryu CM; Choi Y; Choi SJ; Lee E; Choe PG; Moon SM; Park WB; Bang J; Park SW; Park KU; Kim NJ; Oh MD; Kim ES; Kim HB
    Sci Rep; 2024 Jun; 14(1):14960. PubMed ID: 38942780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and efficacy against carbapenem-resistant
    Wang Z; Yang X; Wang H; Wang S; Fang R; Li X; Xing J; Wu Q; Li Z; Song N
    Front Cell Infect Microbiol; 2024; 14():1382145. PubMed ID: 38736748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for mortality in Acinetobacter baumannii bloodstream infections and development of a predictive mortality model.
    Corcione S; Longo BM; Scabini S; Pivetta E; Curtoni A; Shbaklo N; Costa C; De Rosa FG
    J Glob Antimicrob Resist; 2024 Sep; 38():317-326. PubMed ID: 39029658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Case-Control Study of Eravacycline for the Treatment of Carbapenem-Resistant Acinetobacter Infections in Patients With Burn Injuries.
    Alexander C; Hill D
    J Burn Care Res; 2024 Mar; 45(2):487-492. PubMed ID: 37971422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The deadly impact of extreme drug resistance in Acinetobacter baumannii.
    Spellberg B; Bonomo RA
    Crit Care Med; 2014 May; 42(5):1289-91. PubMed ID: 24736340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.